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Abstract
Background: The innate immune Toll-like receptors (TLRs) 2/4 are important players in chronic low-grade
inflammation called metabolic inflammation in obesity and type-2 diabetes (T2D). While TLR2/4 expression changes
associated with metabolic inflammation are known, the adipose tissue expression of endocytic TLR8, which is
expressed by all major macrophage subsets, remain unclear. We, therefore, determined the TLR8 mRNA/protein
expression in the adipose tissue samples from lean, overweight, and obese individuals with or without T2D.
Methods: Subcutaneous fat biopsy samples were collected from 49 non-diabetic (23 obese, 17 overweight, and
nine lean) and 45 T2D (32 obese, ten overweight, and three lean) individuals. TLR8 gene expression was
determined using real-time RT-PCR and TLR8 protein expression was assessed by both immunohistochemistry and
confocal microscopy. The changes in TLR8 expression were compared with those of macrophage markers,
proinflammatory cytokines/chemokines, and surface TLRs/adapter proteins. The data were analyzed using t-test/
Mann-Whitney U-test, Pearson’s correlation, and multiple regression test.
Results: The data show that in obese non-diabetic/T2D individuals, TLR8 gene expression was significantly
upregulated as compared with lean individuals which correlated with body mass index (BMI) and body fat
percentage in non-diabetic population (P < 0.05). As expected, TLR8 adipose tissue protein expression in non-
diabetic/T2D obese individuals was also higher than that of overweight/lean counterparts. In non-diabetic/T2D
individuals, TLR8 gene expression associated (P < 0.05) with the expression of CD68, CD11c, CD86, and CD163
macrophage markers. Also, in these individuals, TLR8 gene expression correlated positively (P < 0.05) with adipose
tissue expression of TNF-α, IL-18, and IL-8 as well as with systemic CRP levels (in non-diabetics). TLR8 expression was
also associated with TLR4/TLR2 and MyD88 expression in the adipose tissue.
Conclusions: The elevated adipose tissue expression of TLR8 in obesity/T2D has consensus with inflammatory
signatures and may thus represent an immune marker of metabolic inflammation.
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Background
The increasing use of energy-dense foods and overnutri-
tion in recent decades has caused the obesity epidemic
to escalate to staggering proportions both in young and
adult populations worldwide [1]. Obesity is marked by a
state of chronic low-grade inflammation, called meta-
bolic inflammation, in which circulatory monocytes infil-
trate the expanding adipose tissue and are differentiated
into the adipose tissue macrophages (ATMs). Macro-
phages in lean mice and humans constitute about 5% of
the cells in adipose tissue whereas during obesity, they
constitute up to 50% of all adipose tissue cells [2]. The
increase in macrophage numbers is accompanied by
macrophage activation and expression of proinflamma-
tory cytokines/chemokines that act by autocrine/para-
crine mechanisms and may induce insulin resistance in
the peripheral tissues [3]. Tumor necrosis factor
(TNF)-α, IL-18, IL-8, and C-reactive protein (CRP) are
considered potential risk factors for the development of
type-2 diabetes (T2D) and its associated metabolic
complications [4, 5].
The pathogen- and nutrient-sensing systems are evolu-
tionarily conserved in most species and hence the immu-
nometabolic regulation remains strongly integrated.
Toll-like receptors (TLRs) play a key role in the initiation
of innate immune responses are regarded as the pattern
recognition receptors that recognize pathogen-associated
molecular patterns expressed by microbial pathogens or
danger-associated molecular patterns expressed by cells
during conditions like cellular stress or viral infection [6].
The emerging evidence points to the role of TLRs in non-
infectious inflammatory conditions such as rheumatoid
arthritis, inflammatory bowel disease, asthma, cancer, and
obesity [7–13]. TLR signaling, except TLR3, activates mye-
loid differentiation factor (MyD)-88 adapter protein which
eventually leads to nuclear factor (NF)-κB activation after
the macromolecular complex formation including IL1R-
associated kinase (IRAK)-1, IRAK-4, tumor necrosis factor-
associated factor (TRAF)-6, and IκB kinase complex [14].
TLR8 is associated with sensing of nucleic acids in-
cluding single-stranded RNA and short double-stranded
RNA that are released within the endosomal compart-
ments or by agonists like imidazoquinolines as shown in
a mouse model study [15]. Since the TLR8 stimulation
was linked to induction of proinflammatory cytokines
(TNF-α, IL-1β, IL-6, and IL-12) in peripheral blood
mononuclear cells (PBMC), dendritic cells (DCs), and
monocytes [16] as well as related with anti-inflammatory
IL-10 production [17], we wanted to know if the TLR8
expression was modulated in metabolic disease as has
been observed for surface TLRs especially, TLR2 and
TLR4. Notably, the changes in the adipose tissue expres-
sion of TLR8 in obesity/T2D are not well understood.
Herein, we present the data showing increased TLR8
expression in the adipose tissue of obese individuals with
or without T2D. We further show that the increased
TLR8 expression was concordant with macrophage




A total of 49 non-diabetic (27 male and 22 female, aged
25–71 years) and 45 T2D individuals (26 male and 19
female, aged 23–72 years) were recruited in the study
through clinics of Dasman Diabetes Institute (DDI),
Kuwait. All participants gave written informed consent
and the study was approved by DDI ethics committee.
Those of age <18 years or with serious lung, kidney, liver,
or cardiovascular disease, or the ones with hematologic
or immune disorders, pregnancy, malignancy or type-1
diabetes were excluded. The participants were sub-
classified based on their body mass index (BMI). The
non-diabetic group comprised of nine lean (BMI =
22.47 ± 2.52 kg/m2; 3 male/6 female), 17 overweight
(BMI = 28.36 ± 1.10 kg/m2; 11 male/6 female), and 23
obese (BMI = 35.00 ± 3.45 kg/m2; 13 male/10 female)
individuals. The T2D group comprised of 3 lean (BMI
= 25.47 ± 0.34 kg/m2; 2 male/1 female), 10 overweight
(BMI = 27.87 ± 1.70 kg/m2; 6 male/4 female), and 32
obese (BMI = 33.69 ± 2.55 kg/m2; 18 male/14 female)
individuals. The comorbidities in non-diabetic individ-
uals included milder, early-stage clinical symptoms of
hypertension (6), hyperlipidemia (1), coronary artery
disease (1), allergy (1), and asthma (2). Similarly, the
comorbidities in T2D patients included minor forms of
hypertension (18), hyperlipidemia (6), coronary artery
disease (2), allergy (2), and asthma (3). The clinico-
demographic data of the study participants are summa-
rized in Table 1.
Anthropometric and physioclinical measurements
Height and weight were measured using calibrated port-
able electronic weighing scales and portable inflexible
height measuring bars; the waist circumference was
measured using constant tension tape. The whole body
composition including body fat percentage, soft lean mass,
and total body water were measured using IOI353 Body
Composition Analyzer (Jawon Medical, South Korea).
Blood pressure was measured by using Omron HEM-
907XL digital automatic sphygmomanometer (Omron
Healthcare Inc. IL, USA). BMI was calculated as follows:
BMI = body weight (kg)/height (m2). Peripheral blood was
collected from overnight-fasted individuals and analyzed
for fasting glucose, glycated hemoglobin (HbA1c), fast-
ing insulin, and lipid profile. Glucose and lipid profiles
were measured using Siemens dimension RXL chemistry
analyzer (Diamond Diagnostics, Holliston, MA, USA).
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Table 1 Patients’ characteristics and clinical data (Groups with significant differences are marked by an asterisk; one-way ANOVA)
Parameter Non-diabetic Diabetic
Lean Overweight Obese Lean Overweight Obese
Total number (N) 9 17 23 3 10 32
Male (N) 3 11 13 2 6 18
Female (N) 6 6 10 1 4 14
Age (Yrs.) 25–53 29–71 26–66 48–58 45–59 23–72
Body mass index (kg/m2) 22.47 ± 2.52* 28.36 ± 1.10* 35.00 ± 3.45* 25.47 ± 0.34 27.87 ± 1.70 33.69 ± 2.55
Body fat percentage 27.73 ± 6.09 33.04 ± 4.95 39.09 ± 4.29 32.10 ± 6.22 31.29 ± 6.08 37.33 ± 5.04
Glucose (mmol/L) 4.94 ± 0.72 5.69 ± 1.63 5.24 ± 0.71 5.80 ± 0.42 9.04 ± 2.22 8.71 ± 2.91
Cholesterol (mmol/L) 5.53 ± 1.04 4.87 ± 0.81 5.05 ± 1.14 5.40 ± 2.55 4.91 ± 1.62 5.03 ± 1.23
High-density lipoprotein (mmol/L) 1.70 ± 0.48 1.20 ± 0.19 1.13 ± 0.24 1.14 ± 0.15 1.12 ± 0.40 1.15 ± 0.30
Low-density lipoprotein (mmol/L) 3.53 ± 0.92 3.14 ± 0.74 3.29 ± 1.01 3.70 ± 2.12 2.89 ± 1.37 2.98 ± 1.10
Triglycerides (mmol/L) 0.64 ± 0.25 1.18 ± 0.67 1.44 ± 0.89 1.25 ± 1.25 1.97 ± 0.83 1.89 ± 1.48
HbA1c (%) 5.74 ± 0.49 5.92 ± 1.70 5.68 ± 0.64 6.00 ± 0.28 7.91 ± 1.96 8.27 ± 1.50
Hypertension (N) 0 2 4 0 3 15
Hyperlipidemia (N) 0 0 1 0 2 4
Coronary artery disease (N) 0 0 1 0 1 1
Allergy (N) 0 0 1 0 0 2
Asthma (N) 1 1 0 0 0 3























































































































































































































































































Fig. 1 Upregulated TLR8 gene expression in the adipose tissue of obese individuals with or without type-2 diabetes. TLR8 gene expression in the
subcutaneous adipose tissue biopsy samples collected from 49 non-diabetic (23 obese, 17 overweight, and nine lean) and 45 type-2 diabetic
(T2D) (32 obese, ten overweight, and three lean) individuals was determined by quantitative real-time RT-PCR as described in Methods.
The representative data from three independent determinations are shown. (a) TLR8 mRNA expression in non-diabetic individuals was
found to be significantly upregulated in the adipose tissue samples of obese as compared with lean individuals (P = 0.01). The increased
TLR8 gene expression correlated positively with (b) body mass index (BMI) (r = 0.36; P = 0.01) and (c) body fat percentage (r = 0.34; P = 0.02). (d) TLR8
mRNA expression in T2D patients was also found to be significantly upregulated in the adipose tissue samples from obese as compared with lean and
overweight subjects combined (P = 0.04). However, in this cohort, TLR8 gene expression did not correlate with (e) BMI (r = 0.20; P = 0.19) and (f) body
fat percentage (r = 0.09; P = 0.54)






































































































































Fig. 2 (See legend on next page.)
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Glycated hemoglobin (HbA1c) was measured by using
Variant™ device (BioRad, Hercules, CA, USA). Plasma
high sensitivity CRP (hsCRP) levels were measured using
ELISA kit (Biovendor, USA). Plasma triglycerides were
also measured using commercial kit (Chema Diagnostica,
Monsano, Italy). All assays were carried out following
instructions as recommended by the manufacturers.
Sample collection
Human adipose tissue samples (~0.5 g) were collected via
abdominal subcutaneous fat pad biopsy lateral to the um-
bilicus using standard surgical method. The biopsy tissue
was further incised into smaller pieces, rinsed in cold PBS,
fixed in 4% paraformaldehyde for 24 h and then embedded
in paraffin for further use. Adipose tissue samples (~50-
100 mg) were also stored at −80 °C in RNAlater until use.
Real-time RT-PCR
Total cellular RNA was purified using RNeasy kit (Qiagen,
Valencia, CA., USA) and following the manufacturer’s
instructions. Samples (1 μg each) were reverse transcribed
into cDNA as instructed (High Capacity cDNA Reverse
Transcription kit; Applied Biosystems, CA, USA). To
perform real-time RT-PCR, cDNA samples (50 ng each)
were amplified (40 cycles) using TaqMan® Gene Expres-
sion MasterMix (Applied Biosystems, CA, USA) and
gene-specific 20× TaqMan gene expression assays as fol-
lows: (TLR8) Hs00152972_m1; (CD68) Hs02836816_g1;
(CD11c) Hs00174217_m1; (CD86) Hs01567026_m1; (CD
163) Hs00174705_m1; (TNF-α) Hs01113624_g1; (IL-18)
Hs01038788_m1; (IL-8) Hs00174103_m1; (TLR2) Hs018
72448_s1; (TLR4) Hs00152939_m1; (MyD88) Hs0157
3837_g1; and (GAPDH) Hs03929097_g1 (Applied Biosys-
tems, CA, USA) containing forward and reverse primers
and target-specific TaqMan® MGB probe labeled with
FAM dye at the 5’ end and NFQ-MGB at the 3’ end of the
probe using 7500 Fast Real-Time PCR System (Applied
Biosystems, CA, USA). Each cycle involved denaturation
(15 s at 95 °C), annealing/extension (1 min at 60 °C) after
UDG (2 min at 50 °C) and AmpliTaq gold enzyme
(10 min at 95 °C) activation. The amplified GAPDH
expression was used as internal control to normalize in-
dividual sample differences. TLR8 gene expression level
relative to control (lean adipose tissue) was calculated
using 2-ΔΔCt method and the relative mRNA expression
was expressed as fold expression over the average control
gene expression taken as one.
Immunohistochemistry
Paraffin-embedded adipose tissue sections (4 μm)
were deparaffinized in xylene and rehydrated through
descending grades (100, 95 and 75%) of ethanol to
water. Antigen was retrieved from samples by boiling
in retrieval solution (pH6.0; Dako, Glostrup, Denmark) for
8 min in pressure cooker followed by cooling for 15 min.
After PBS washing and blocking in 3% H2O2 for 30 min,
5% nonfat milk for 1 h, and 1% BSA solution for 1 h,
samples were treated overnight at room temperature with
primary antibody (1:800 diluted anti-human TLR8 mouse
monoclonal antibody; Abcam® ab85859). After two washes
with PBS-0.5% Tween, samples were treated for 1 h with
HRP-conjugated goat anti-mouse secondary antibody
(EnVision™ Kit, Dako, Glostrup, Denmark) and color was
developed using 3,3’-diaminobenzidine (DAB) substrate.
Specimens were washed in running tap water, coun-
terstained with Harris hematoxylin, dehydrated through
ascending grades (75, 95, and 100%) of ethanol, cleared in
xylene, and mounted in dibutyl phthalate xylene (DPX).
For quantitative analysis of TLR8 protein expression, the
entire adipose tissue sections (100×; Panoramic Scan, 3D-
HISTECH, Hungary) were used to quantify immunohisto-
chemical staining in all subdivided sample regions that
were outlined using Aperio ImageScope software (Aperio
Vista, CA, USA). On average, 700 cells per sample were
counted excluding the connective tissue and blood vessels.
Aperio-positive pixel count algorithm (version 9) was used
for quantitative analysis of TLR8 immunostaining in the re-
gions sampled. The number of positive pixels was normal-
ized to the number of total (positive and negative) pixels to
account for variations in the size of the region sampled.
Color and intensity thresholds were established to detect
the specific immunostaining as positive and the background
staining as negative pixels. Once the conditions were set, all
slides were analyzed using same parameters.
Confocal microscopy
Formalin-fixed paraffin-embedded adipose tissue sec-
tions (8 μm) were immunolabeled as described before.
(See figure on previous page.)
Fig. 2 Elevated TLR8 protein expression in the adipose tissue samples from obese and overweight non-diabetic individuals. TLR8 protein expression
in the subcutaneous adipose tissue samples from 15 non-diabetic individuals comprising lean, overweight and obese, five each, was
detected by immunohistochemistry (IHC) and confirmed by confocal microscopy as described in Methods. TLR8 protein expression in the
adipose tissue samples was quantified using Aperio ImageScope software (Aperio Vista, CA, USA) and algorithm (version 9); on average,
700 cells were counted for each sample. The representative data from three independent determinations are shown. TLR8 protein expression is shown
by using (a) immunohistochemistry (arrows); and (b) confocal microscopy where red color represents TLR8-specific staining and blue color represents
nuclei staining (40× magnification). c TLR8 protein expression quantified as IHC staining intensity shows significantly higher expression in
obese (P = 0.005) and overweight (P = 0.01) individuals as compared with lean counterparts. (d) The adipose tissue TLR8 protein expression
in non-diabetics correlates with BMI (r = 0.64 P = 0.01)
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Fig. 3 (See legend on next page.)
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Following antigen retrieval and blocking, samples were
treated overnight at room temperature with primary
antibody (1:100 diluted anti-TLR8 monoclonal antibody;
abcam® ab85859). After two washes with PBS-0.05%
Tween, samples were incubated for 1 h with secondary
antibody (1:200 diluted goat anti-mouse Alexa Fluor®
647-conjugated antibody; Abcam® ab150115) and washed
three times in PBS. Samples were counterstained with 4’,6-
diamidino- 2-phenylindole (DAPI) (Vectashield, Vector
Laboratories, H-1500) and mounted. For image processing
and analysis, confocal images were collected (Inverted
Zeiss LSM710 spectral confocal microscope, Carl Zeiss,
Gottingen, Germany) using EC Plan-Neofluar 40×/1.30 oil
DIC M27 objective lens. Samples were excited using a
488 nm diode-pumped solid-state laser and the 405 nm
line of an argon ion laser. After laser excitation, optimized
emission detection bandwidths were configured using
Zeiss Zen 2010 control software.
Statistical analysis
Data were expressed as mean ± SEM values unless other-
wise indicated and statistical analysis was performed
using GraphPad Prism software (La Jolla, CA, USA) and
SPSS for Windows version 19.01 (IBM SPSS Inc. USA).
Unpaired Student t-test and Mann-Whitney U-test were
used to compare group means. Correlation and stepwise
multiple regression were performed to determine associ-
ations between different variables. One-way ANOVA
was used to identify groups that had significant differ-
ences. All P-values <0.05 were considered significant.
Results
Increased adipose tissue TLR8 gene expression in
diabetic/non-diabetic obese individuals
Whereas the changes in TLR2/TLR4 expression in the
adipose tissue are regarded as important actors in meta-
bolic inflammation, the changes in the adipose tissue
expression of endocytic TLR8 in obesity/T2D remain
unclear. To this end, we found that in non-diabetic indi-
viduals, TLR8 mRNA expression in the adipose tissue
was significantly upregulated in obese as compared with
lean counterparts (P = 0.01) (Fig. 1a) and this increase
correlated positively with phenotypes of corpulence,
such as BMI (r = 0.36, P = 0.01) (Fig. 1b) and body fat
percentage (r = 0.34, P = 0.02) (Fig. 1c). The adipose tis-
sue TLR8 mRNA expression was also found to be higher
in obese T2D patients as compared with lean/overweight
population (P = 0.04) (Fig. 1d). The expression of TLR8
in the diabetic cohort did not associate with parameters
of corpulence including BMI (r = 0.19, P = 0.19) (Fig. 1e)
and body fat percentage (r = 0.09, P = 0.54) (Fig. 1f ) and,
instead, it showed an association with the metabolic
parameters including glycemia and glycated hemoglobin
(HbA1c) levels. (Additional file 1).
Elevated adipose tissue TLR8 protein expression in
obesity
We further asked whether the TLR8 protein expression
was also elevated in the adipose tissue in obesity. As
expected, we found that the adipose tissue TLR8 protein
expression in 14 non-diabetic individuals as analyzed by
immunohistochemistry (shown for two individuals per
group; Fig. 2a) and confirmed by confocal microscopy
(shown for one individual in each group; Fig. 2b) was
significantly elevated in both obese (P = 0.005) and
overweight (P = 0.01) subjects as compared with lean
controls (Fig. 2c). The elevated TLR8 protein expression
in this cohort was also found to correlate with BMI
(r = 0.64, P = 0.01) (Fig. 2d). Similarly in 13 T2D indi-
viduals, the adipose tissue TLR8 protein expression
determined by immunohistochemistry (shown for two in-
dividuals per group; Fig. 3a) and confirmed by confocal
microscopy (shown for one individual in each group;
Fig. 3b) was found to be elevated in obese (P = 0.0001)
and overweight (P = 0.003) as compared with lean coun-
terparts (Fig. 3c); and TLR8 protein expression associated
with BMI in diabetic cohort (r = 0.87, P < 0.0001) (Fig. 3d).
As shown in Additional file 2, overall, a highly significant
positive correlation was found between gene and protein
expression of TLR8 (r = 0.86, P < 0.0001).
TLR8 gene expression correlates with monocyte/
macrophage markers in the adipose tissue
We next asked if the increased TLR8 mRNA expression
in the adipose tissue was concordant with a local inflam-
matory profile marked by an increased expression of
monocyte/macrophage markers. In this regard, we found
that in non-diabetic individuals, the adipose tissue TLR8
(See figure on previous page.)
Fig. 3 Increased TLR8 protein expression in the adipose tissue samples from obese and overweight type-2 diabetic (T2D) individuals. TLR8 protein
expression in the subcutaneous adipose tissue samples from 13 T2D patients comprising three lean, five overweight and five obese individuals
was detected by immunohistochemistry (IHC) and confirmed by confocal microscopy as described in Methods. TLR8 protein expression in the
adipose tissue samples was quantified by using Aperio ImageScope software (Aperio Vista, CA, USA) and algorithm (version 9); while on average,
700 cells were counted for each sample. The representative data from three independent determinations are shown. TLR8 protein expression is
shown by using (a) immunohistochemistry (arrows); (b) confocal microscopy wherein red color represents TLR8-specific staining and blue color
represents nuclei staining (40× magnification). (c) TLR8 protein expression quantified as IHC staining intensity shows significantly higher expres-
sion in obese (P = 0.0001) and overweight (P = 0.003) individuals as compared with lean counterparts. (d) The adipose tissue TLR8 protein expres-
sion in T2D patients correlates with BMI (r = 0.87 P < 0.0001)
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Fig. 4 (See legend on next page.)
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gene expression correlated positively with the gene ex-
pression of CD68 (r = 0.60, P < 0.0001) (Fig. 4a), CD11c
(r = 0.61, P < 0.0001) (Fig. 4b), CD86 (r = 0.75, P < 0.0001)
(Fig. 4c), and CD163 (r = 0.52, P = 0.0001) (Fig. 4d). Also
in T2D patients, TLR8 gene expression correlated po-
sitively with CD68 (r = 0.61, P < 0.0001) (Fig. 4e), CD11c
(r = 0.52, P = 0.0002) (Fig. 4f), CD86 (r = 0.77, P < 0.0001)
(Fig. 4g), and CD163 (r = 0.72, P < 0.0001) (Fig. 4h). While
analyzing in a total population of 94 individuals (49 non-
diabetic and 45 diabetic), the adipose tissue expression of
macrophage markers CD68, CD86, and CD163 associated
positively with BMI (P < 0.05) (Additional file 3); however,
CD11c did not associate with BMI (r = 0.12, P = 0.21)
(data not shown).
Increased TLR8 gene expression in obese adipose tissue
associates with an inflammatory profile
We further wanted to know if the elevated TLR-8 gene
expression in obese adipose tissues was in agreement
with the increased expression of inflammatory cyto-
kines/chemokines and related markers. To this end, we
found that in non-diabetic persons, the adipose tissue
TLR8 mRNA expression associated positively with gene
expression of TNF-α (r = 0.45, P = 0.001) (Fig. 5a), IL-18
(r = 0.29, P = 0.04) (Fig. 5b), IL-8 (r = 0.46, P = 0.001)
(Fig. 5c), and plasma CRP levels (r = 0.36, P = 0.02)
(Fig. 5d). In T2D patients, TLR8 gene expression co-
rrelated with TNF-α (r = 0.31, P = 0.04) (Fig. 5e), IL-18
(r= 0.53, P = 0.0001) (Fig. 5f), and IL-8 (r = 0.47, P = 0.001)
(Fig. 5g); whereas, no correlation was found with plasma
CRP levels (r = −0.04, P = 0.81) (Fig. 5h).
TLR8 expression in the adipose tissue is linked with TLR2/
TLR4 and MyD88 expression
The innate immune TLRs have potential to play direct
or indirect roles in obesity- or T2D-associated metabolic
inflammation and, therefore, we asked whether the adi-
pose tissue TLR8 gene expression was linked with the
expression of other immunometabolic TLRs such as
TR2 and TLR4 as well as with downstream MyD88
adapter protein. To this effect, we found that TLR8 gene
expression in non-diabetic individuals was positively as-
sociated with the adipose tissue gene expression of TLR2
(r = 0.55, P < 0.0001) (Fig. 6a), TLR4 (r = 0.28, approaching
the level of statistical significance with P = 0.06) (Fig. 6b),
and MyD88 (r = 0.55, P < 0.0001) (Fig. 6c). Similarly, in
T2D patients as well, TLR8 gene expression was associ-
ated with that of TLR2 (r = 0.76, P < 0.0001) (Fig. 6d),
TLR4 (r = 0.66, P < 0.0001) (Fig. 6e), and MyD88 expres-
sion (r = 0.52, P = 0.0002) (Fig. 6f).
Additionally, within-group correlations of the TLR8
gene expression with other inflammatory markers in the
adipose tissue were also determined and the data are
summarized in Additional file 4.
Discussion
The emerging evidence supports that immune and meta-
bolic systems are tightly integrated and the innate im-
mune TLRs can be directly or indirectly activated by
overnutrition leading to metabolic inflammation. Re-
garding the adipose tissue changes in TLR8 expression
in obesity/T2D, our data show that in non-diabetic
obese individuals, the upregulated TLR8 mRNA ex-
pression correlated with corpulence-related phenotypes
including BMI and body fat percentage. However, the
altered TLR8 expression did not associate with corpu-
lence phenotypes in T2D individuals that happen to be
more heterogeneous due to presence of dyslipidemia
and related complications. Instead, TLR8 gene expres-
sion in this cohort was associated with metabolic traits
e.g. glycemia and HbA1c levels. It is not clear whether
hyperglycemia could upregulate TLR8 expression, and a
few studies both in humans and mice have shown the
link between hyperglycemia and TLR2/4 induction and
upregulation [18, 19]. Our data also show elevated TLR8
protein expression in the adipose tissue in obesity with/
without T2D and, notably, a good agreement (r = 0.86,
P < 0.0001) was found between gene and protein ex-
pression of TLR8. Although, the global expression of
TLR8 detected in the adipose tissue may relate to a variety
of cells present in this compartment, it is mainly expressed
by monocytes/macrophages, mast cells, and myeloid den-
dritic cells [20]. The increased TLR8 expression detected
by immunohistochemical staining was found on in-
flammatory cell aggregates that were visible as crown
like structures (CLS) surrounding the degenerating
adipocytes in obese adipose tissue samples (arrow
heads point to CLS).
Next, we found that the increased TLR8 gene expres-
sion in the adipose tissues in obesity/T2D paralleled
with enhanced expression of monocyte/macrophage
markers such as CD68, CD11c, CD86, and CD163. The
(See figure on previous page.)
Fig. 4 TLR8 gene expression in the adipose tissue of non-diabetic/diabetic individuals correlates with monocyte/macrophage markers. The adipose
tissue gene expression of TLR8 and monocyte/macrophage markers (CD68, CD11c, CD86, and CD163) in 49 non-diabetic (ND) and 45 type-2 diabetic
(T2D) individuals was determined by using quantitative real-time RT-PCR as described in Methods. The representative data from three independent
determinations show that TLR8 gene expression correlated positively/significantly with the local expression of (a) CD68[ND] (r = 0.60, P < 0.0001);
(b) CD11c[ND] (r = 0.61, P < 0.0001); (c) CD86[ND] (r = 0.75, P < 0.0001); (d) CD163[ND] (r = 0.52, P = 0.0001); (e) CD68[T2D] (r = 0.61, P < 0.0001); (f)
CD11c[T2D] (r = 0.52, P = 0.0002); (g) CD86[T2D] (r = 0.77, P < 0.0001); and (h) CD163[T2D] (r = 0.72, P < 0.0001)




Fig. 5 (See legend on next page.)
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CD68, CD11c, and CD86 are markers of inflammatory
or M1-type macrophages and CD163 is a hemoglobin-
haptoglobin scavenger receptor. We found that the adi-
pose tissue expression of these markers was associated
with corpulence phenotype i.e. BMI which meant that
obesity could be a positive modulator of monocyte/macro-
phage influx into the adipose tissue which is known to se-
crete chemotactic adipokines including CC-chemokine
ligand (CCL)-2 or macrophage chemoattractant protein
(MCP)-1 as shown earlier by a diet-induced obesity study
in mice [21]. Our data showing elevated macrophage
markers expression in the adipose tissue in obesity/T2D
are corroborated, at least in part, by other studies as well
[2, 22, 23]. Of note, Devevre et al. reported three distinct
monocytic populations in human obesity named as clas-
sical, intermediate, and non-classical monocytes while a
2–4 fold increased expression of TLR4/TLR8 was found
in all three subsets [24]. These observations partially
(See figure on previous page.)
Fig. 5 Increased adipose tissue TLR8 gene expression correlates with typical inflammatory markers. The adipose tissue gene expression of TLR8
and signature inflammatory cytokines/chemokines (TNF-α, IL-18, and IL-8) was determined in 49 non-diabetic (ND) and 45 type-2 diabetic (T2D)
individuals using quantitative real-time RT-PCR while plasma high-sensitivity C-reactive protein (CRP) levels were determined using commercial
ELISA kit and following the manufacturer’s recommendations. The representative data from two independent determinations show that TLR8
mRNA expression was associated with the expression of (a) TNF-α[ND] (r = 0.45, P = 0.001); (b) IL-18[ND] (r = 0.29, P = 0.04); (c) IL-8[ND] (r = 0.46, P = 0.001);
(d) Plasma CRP[ND] (r = 0.36, P = 0.02); (e) TNF-α[T2D] (r = 0.31, P = 0.04); (f) IL-18[T2D] (r = 0.53, P = 0.0001); and (g) IL-8[T2D] (r = 0.47, P = 0.001). (h) TLR8
gene expression in T2D patients did not correlate with plasma CRP levels (r = −0.04, P = 0.81). Due to missing plasma samples, TLR8 correlation with
plasma CRP levels is shown for 38 ND and 32 T2D individuals
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Fig. 6 TLR8 mRNA expression in the adipose tissue associates with local gene expression of TLR2, TLR4, and MyD88. The adipose tissue gene
expression of TLR2, TLR4, TLR8, and MyD88 was determined in 49 non-diabetic and 45 type-2 diabetic (T2D) individuals by using quantitative
real-time RT-PCR as described in Methods. The representative data from two independent determinations show that TLR8 gene expression was
positively associated with that of (a) TLR2 (r = 0.55, P < 0.0001); (b) TLR4 (r = 0.28, approaching significance with P = 0.06); and (c) MyD88 (r = 0.55,
P < 0.0001). Similarly, in T2D patients, TLR8 gene expression was found to be associated with (d) TLR2 (r = 0.76, P < 0.0001); (e) TLR4 (r = 0.66,
P < 0.0001); and (f) MyD88 expression (r = 0.52, P = 0.0002). Due to missing data, TLR8 correlation with TLR4 is shown for 44 T2D patients
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support our data showing enhanced TLR8 expression in
the obese adipose tissue.
We also found that TLR8 gene expression was positively
associated with inflammatory cytokines/chemokine ex-
pression in the adipose tissue as well as with circulatory
levels of inflammatory biomarker CRP. The white adipose
tissue is a site for excessive energy storage and active bio-
synthesis of adipokines that act via autocrine/paracrine
mechanisms in adipocyte-macrophage crosstalk to amplify
the local and systemic inflammatory responses in obesity/
T2D [25]. The proinflammatory cytokines TNF-α and IL-
18 are known to be elevated in obesity/T2D [26, 27] while
IL-8 or CXC chemokine ligand (CXCL)-8 is an inflam-
matory protein and increased circulatory numbers of IL8-
expressing monocytes were also reported in human
obesity [24]. CRP is a typical systemic inflammatory
marker and its increased levels were linked with obesity,
blood pressure, and hyperlipidemia [28]. The proinflam-
matory bioactive proteins TNF-α, IL-18, and IL-8 are
intertwined through cross-regulatory mechanisms. TNF-α
was found to regulate IL-8 in human adipose tissue [29]
and IL-18 in human adipocytes [30] whereas, IL-18 in-
duced IL-8 and IL-1β in human monocytes in a TNFα-
dependent mechanism [31]. Our data showing increased
TNF-α, IL-18, and IL-8 expression in obesity are in agree-
ment with studies showing induction of these proinflam-
matory proteins in obese humans [32, 33]. Our data
further show an association between these inflammatory
adipokines and TLR8 expression in the adipose tissue;
however, CRP levels in T2D individuals did not correlate
with TLR8 gene expression and we speculate that this
discrepancy may be due to T2D-associated comorbid fac-
tors such as liver dysfunction, central adiposity, hypergly-
cemia, and insulin resistance. This line of argument is
supported by the observation that studies on plasma CRP
levels in T2D patients show heterogeneity in their findings
[34, 35]. Also, we cannot rule out plausible effects of anti-
diabetic pharmacologic interventions on systemic levels of
CRP [36]. Multiple stepwise linear regression analysis of
our data revealed that CD11c, CD86, and IL-8 independ-
ently predicted TLR8 gene expression in the non-diabetic
while CD11c predicted TLR8 gene expression in the
diabetic subjects. Additionally, analysis of the within-
group associations of TLR8 gene expression with other
inflammatory markers in the adipose tissue indicates that
obesity- and T2D-associated inflammatory changes in-
cluding macrophage infiltration, upregulated expression of
proinflammatory cytokines/chemokines, increased surface
TLRs (TLR2/4) and downstream adapter protein MyD88
may be linked, at different levels, to the induction/upregu-
lation of TLR8 in the adipose tissue.
The altered TLR expression observed in metabolic
disease conditions is likely to have pathological co-
nsequences. We show that TLR8 gene expression was
positively associated with TLR2, TLR4, and MyD88
expression in the adipose tissue. The upregulation of
TLRs and inflammatory cytokine production have been
also reported by previous studies in humans [13, 37].
TLR2/4 bind to free fatty acids in addition to other
known ligands and MyD88 is a downstream adapter
protein which is involved in TLR-mediated signaling
except TLR3 [38]. While several studies point to a link
between TLR upregulation and metabolic inflammation
[13, 37, 39], our data add the adipose tissue changes in
endocytic TLR8 as an immune marker to the growing
list of novel correlates of metabolic inflammation. Hu-
man TLR8 is a part of the nucleic acid-sensing TLRs
that recognize viral ss/ds RNAs [40] and bacterial RNA
[41]; however, TLR8 agonist(s) associated with obesity/
T2D are still not known. Therefore, TLR8 expression
changes need to be further investigated with regard to
putative agonists like cellular RNAs and alarmins (e.g.
HMGB1) which are known to be released during lipolysis
in morbid obesity [42]. Besides, the present study is also
limited by certain factors as follows: (1) small cohort size
for each BMI group; (2) the lack of data expressing func-
tional changes in relation to altered TLR8 expression in
the adipose tissue; and (3) the data represent TLR8 global
changes in the adipose tissue in obesity/T2D and hence
selective expression of TLR8 in adipocytes and macro-
phages remains unknown.
Conclusions
Taken together, the present data show significantly ele-
vated TLR8 mRNA and protein expression in the adipose
tissue in obesity/T2D. Based on consensus with other
inflammatory markers, TLR8 expression changes in the
obese adipose tissue may represent a novel molecular
signature of metabolic inflammation.
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